Advertisement
Home2024-01-11T09:26:42-05:00

Top Story

  • Medical Affairs
    April 1st, 2024

    US lawmakers have raised alarms about BGI, a major Chinese genomics firm, allegedly attempting to skirt regulatory oversight and potential political backlash by creating subsidiaries in the United States. Representatives Mike Gallagher and Raja Krishnamoorthi have specifically requested the inclusion of BGI's subsidiaries, Innomics and STOmics, [...]

Advertisement

Featured Webinars

Handpicked Promotions & Highlights

Latest in Catalyst News powered by BioPharmCatalyst

04/25/2024 04:46 PM ET

Processa Pharmaceuticals BCDA date announcement

BioCardia has an announcement scheduled for December 31, 2024 regarding their recent Phase 3 trial of CardiAMP (BCDA-02). The community is currently bullish on the prospects of progression, as the bulls outnumber bears by five [...]

Read More
04/25/2024 04:46 PM ET

Elicio Therapeutics ELTX date announcement

Now that the Phase 1/2 trial of ELI-002 - (AMPLIFY-7P) is completed, Elicio Therapeutics will announce their top-line results on June 30, 2024. Our predictive system gives the drug a 60.9% chance of making it [...]

Read More
04/25/2024 04:46 PM ET

Vistagen Therapeutics VTGN results announcement

Vistagen Therapeutics provided an update to their Phase 2a trial for PH15. Our analysts provided the following summary:

"Phase 2a data reported that treatment demonstrated a statistically significant improvement in reaction time compared to placebo [...]

Read More
04/25/2024 04:46 PM ET

BeiGene Ltd. BGNE date announcement

BeiGene Ltd. already had seven catalyst announcements coming up, but they added another one today. It will be announcing top-line results for their recent Phase 1a trial for BGB‑15025 monotherapy and in combination with tislelizumab [...]

Read More

Receive essential insights, resources and content direct to your inbox

Hit subscribe to stay informed!

Go to Top